UBS has maintained its ‘Buy’ rating on Sun Pharma, setting a target price of ₹2450, indicating a strong upside potential. UBS expects specialty products to contribute over 30% of the company’s profits in the next three years, which could drive a significant re-rating of the stock.
Additionally, the brokerage highlights Sun Pharma’s strong cash flow and the positive impact of upcoming generic launches, including Lanreotide and Tolvaptan, which are expected to boost the company’s performance.
Current market price (CMP): ₹1,910.05 as of 9:10 AM, Oct 7, 2024
Disclaimer: Stock market investments are subject to market risks. The information provided here is for informational purposes only and should not be considered as financial advice. Please consult with a financial advisor before making any investment decisions.
